Deepa Prasad
President, Chief Executive Officer

Deepa brings over 20 years of healthcare experience spanning venture capital, investment banking, operations, and legislation. She most recently served as Managing Director at WestRiver Group. She currently sits on the Board of Design Therapeutics (Nasdaq: DSGN) and is an Independent Advisor to Equilibre Biopharmaceuticals. In June 2021, Deepa was awarded the Falk Marques General Partners Rising Star Award sponsored by Deloitte. Previous to WestRiver, Deepa’s roles included Chief of Staff at Blue Shield, Regional VP for Optum, VP of Financial Strategy and Business Development at Coherus Biosciences (Nasdaq: CHRS) and several years in biotech investment banking executing private placements and buyside/sellside M&A. She earned her bachelor’s degree in Business Administration from the University of California, Berkeley and her MBA from the Kellogg School of Management at Northwestern University with an emphasis in Health Industry Management.

Carmen Valcarce, Ph.D.
Executive Vice President, Chief Scientific Officer

Carmen has more than 30 years of pharmaceutical research and development experience focused in the metabolic space. During her career, Carmen has managed more than 12 INDs and has run numerous positive clinical studies. Carmen was a member of the vTv IPO team, having joined the company from Novo Nordisk as a result of vTv’s former partnership with Novo. Carmen is an inventor on more than 20 patents and patent applications and an author on numerous peer-reviewed scientific publications. Carmen obtained her Ph.D. at the Universidad Autonoma de Madrid, Spain in 1988 under the direction of Prof. Jose M. Cuezva in the field of metabolic diseases.

Rudy Howard, CPA
Executive Vice President, Chief Financial Officer

Rudy has spent more than 20 years as the Chief Financial Officer of a publicly-traded company. As CFO, Rudy has led three companies through initial public offerings, including vTv, raising more than $500 million in the public markets. Rudy has played a significant role in more than 30 M&A transactions over the course of his career. Prior to joining the Company, Rudy served as Chief Financial Officer of SciQuest, Inc., an international spend management software company. Before joining SciQuest, he was CFO of MDS Pharma Services, a multi-national pharmaceutical services organization. He has also served as CFO for a number of other public and private multi-national companies in the life sciences and software industries, including Pharmaceutical Product Development (PPD), a global pharmaceutical organization. Rudy is a certified public accountant and received his B.A. in accounting from North Carolina State University.

Trey Lambert, J.D. MBA
SVP, General Counsel

Trey joined the team at vTv in 2016 shortly after the company’s initial public offering. As General Counsel, he oversees and manages the company’s legal matters, including corporate governance, securities compliance and SEC reporting, partnering and licensing transactions, financings, and clinical trial contracting. Prior to vTv, Trey was an associate at Latham & Watkins LLP in its Washington, D.C. office and at Womble Bond Dickinson in its Winston-Salem, NC office, working on corporate finance transactions. Before beginning his legal career, Trey was an analyst for the private equity firm Five Points Capital, sourcing and executing lower middle-market equity and debt transactions. Trey received his J.D. from the University of North Carolina at Chapel Hill School of Law, an MBA from UNC Chapel Hill’s Kenan Flagler Business School, and BS degrees in Business Administration and Economics from UNC Chapel Hill.

Aaron Burstein, PharmD
SVP, Clinical Development

Aaron has more than 24 years of clinical research and drug development experience across biotech, large pharma, academia and the federal government. Aaron has supported more than 60 clinical trials across Phases 1-4. He is an author on nearly 50 peer-reviewed scientific publications. Prior to his current position at vTv Therapeutics, Aaron was Senior Director at Pfizer where he held various positions of increasing responsibility within the Clinical and Developmental Operations organizations, with a focus on investigational products for the central nervous system. Aaron obtained his BS and Pharm.D. degrees from the State University of New York at Buffalo and completed his post-doctoral research fellowship at the Dent Neurologic Institute. Aaron is a Fellow of the American College of Clinical Pharmacy.

Robert Andrews, Ph.D.
SVP Chemistry, Pharmaceutical Development and Quality

Rob obtained his Ph.D. at the University of South Carolina in 1986 under the direction of Prof. James Marshall and completed postdoctoral studies in 1988 with Prof. Albert Meyers at Colorado State University. Rob joined Glaxo Research and Development in 1988, pursuing orally active phospholipase A2 inhibitors and therapeutic agents for benign prostatic hyperplasia (BPH). With Glaxo Wellcome Rob progressed to the area of proteases and his team discovered potent inhibitors of tumor necrosis factor – alpha convertase (TACE) possessing oral activity in animal models of inflammatory disease. Rob is the author of numerous papers and presentations, and is an inventor on numerous patents and patent applications.

Samuel Rollins, Ph.D.,J.D.
SVP, Intellectual Property

Sam earned a Bachelor of Science degree in Chemistry from the University of North Carolina at Chapel Hill and a Ph.D. in Chemistry from Colorado State University under the direction of Prof. Robert M. Williams. His doctoral thesis was directed to the design and stereocontrolled synthesis of an eight-membered ring precursor to a photo-triggered mitosene. Following graduate school, Sam earned a Juris Doctorate from Wake Forest University School of Law and practiced patent law at Kilpatrick Stockton LLP. While practicing at Kilpatrick Stockton, he worked with clients in all aspects of patent prosecution, with an emphasis on chemistry, particularly pharmaceutical products and targets, as well as other small molecules (e.g., dyes, probes and binding agents). Sam also worked in the strategic development of patent portfolios and provided due diligence reviews of targeted companies and technology.